Loading...
XNAS
SKYE
Market cap123mUSD
Jul 11, Last price  
3.98USD
1D
1.02%
1Q
182.27%
IPO
42.14%
Name

Skye Bioscience Inc

Chart & Performance

D1W1MN
No data to show
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
132.94%
Rev. gr., 5y
%
Revenues
0k
16,243339,92600000000000
Net income
-27m
L-29.43%
4,509-120,403-2,734,166-4,841,161-3,178,093-3,094,298-19,194,2361,051,825-6,560,699-8,522,182-19,481,602-37,644,784-26,567,123
CFO
-25m
L+80.89%
1,928-14,495-1,755,208-3,727,989-3,552,941-3,298,213-3,943,014-6,027,941-6,054,131-6,474,888-12,744,072-13,952,178-25,237,480
Earnings
Aug 07, 2025

Profile

Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 that is in preclinical trials to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. was founded in 2012 and is headquartered in San Diego, California.
URL
https://skyebioscience.com/
IPO date
Feb 24, 2014
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
36,427
13,672
12,221
Unusual Expense (Income)
NOPBT
(36,427)
(13,672)
(12,221)
NOPBT Margin
Operating Taxes
10
4
7
Tax Rate
NOPAT
(36,438)
(13,675)
(12,228)
Net income
(26,567)
-29.43%
(37,645)
93.23%
(19,482)
128.60%
Dividends
Dividend yield
Proceeds from repurchase of equity
83,557
11,735
2
BB yield
-80.92%
-61.58%
Debt
Debt current
182
4,444
1,927
Long-term debt
729
414
79
Deferred revenue
Other long-term liabilities
1,749
Net debt
(67,505)
3,602
761
Cash flow
Cash from operating activities
(25,237)
(13,952)
(12,744)
CAPEX
(1,604)
(13)
(28)
Cash from investing activities
(246)
6,596
5,214
Cash from financing activities
83,562
16,443
(209)
FCF
(37,101)
(15,983)
(10,904)
Balance
Cash
68,416
1,256
1,245
Long term investments
Excess cash
68,416
1,256
1,245
Stockholders' equity
(130,919)
(104,370)
(65,824)
Invested Capital
199,526
106,854
64,743
ROIC
ROCE
1,130.59%
EV
Common stock shares outstanding
36,487
7,006
1,984
Price
2.83
4.04%
2.72
 
Market cap
103,257
441.85%
19,056
 
EV
35,752
22,659
EBITDA
(36,129)
(13,548)
(12,106)
EV/EBITDA
Interest
749
906
665
Interest/NOPBT